In conclusion, our study suggests that further study of RBM5, EGFR and KRAS gene function and inter-relationships LXH254 clinical trial will provide a better understanding of the role these genes play in NSCLC development and progression. Misc Hong Liang and Jie Zhang contributed equally to this work Acknowledgements This work was supported by the grant from the National Natural Science Foundation of China for KW (No. 81071919)

and the grant from the National Natural Science Foundation of China for JZ (No. 30971315). References 1. Mountain CF: The international system for staging lung cancer. Semin Surg Oncol 2000, 18:106–115.PubMedRAD001 clinical trial CrossRef 2. Parkin DM, Bray F, Ferlay J, Pisani P: Global cancer statistics, 2002. Quisinostat CA Cancer J Clin 2005, 55:74–108.PubMedCrossRef 3. Borczuk AC, Gorenstein L, Walter KL, Assaad AA, Wang L, Powell CA: Non-small-cell lung cancer molecular signatures recapitulate lung developmental pathways. Am J Pathol 2003, 163:1949–1960.PubMedCrossRef 4. Hui HP: Population-based differences in treatment outcome following anticancer drug therapies. Lancet 2010, 11:75–84.CrossRef 5. Brambilla E, Travis WD, Colby TV, Corrin B, Shimosato Y: The new World Health Organization classification of lung tumours. Eur Respir J

2001, 18:1059–1068.PubMedCrossRef 6. Wang L, Xiong Y, Sun Y, Fang Z, Li L, Ji H, Shi T: HLungDB: an integrated database of human lung cancer research. Nucleic Acids Res 2010, 38:665–669.CrossRef 7. Herbst RS, Heymach JV, Lippman SM: Molecular origins of cancer: lung cancer. N Engl J Med 2008, 359:1367–1380.PubMedCrossRef 8. Soonthornthum T, Arias-Pulido Farnesyltransferase H, Joste N, Lomo L, Muller C, Rutledge T, Verschraegen C: Epidermal growth factor receptor as a biomarker for cervical cancer. Ann Oncol 2010, 10:1–13. 9. Ciardiello F, Tortora G: EGFR antagonists in cancer

treatment. N Engl JMed 2008, 358:1160–1174.CrossRef 10. Hirsch FR, Varella-Garcia M, Cappuzzo F: Predictive value of EGFR and HER2 overexpression in advanced non-small-cell lung cancer Predictive value of EGFR/HER2. Oncogene 2009, 28:32–37.CrossRef 11. Costa DB, Schumer ST, Tenen DG, Kobayashi S: Differential responses to erlotinib in epidermal growth factor receptor (EGFR)-mutated lung cancers with acquired resistance to gefitinib carrying the L747S or T790M secondary mutations. J Clin Oncol 2008, 26:1182–1186.PubMedCrossRef 12. Suda K, Tomizawa K, Mitsudomi T: Biological and clinical significance of KRAS mutations in lung cancer: and oncogenic driver that contrasts with EGFR mutation. Cancer Metastasis Rev 2010, 29:49–60.PubMedCrossRef 13. Heidorn SJ, Milagre V, Whittaker S, Nourry A, Niculescu-Duvas I, Dhomen N, Hussain J, Reis-Filho JS, Springer CJ, Pritchard C, Marais R: Kinase-Dead BRAF and Oncogenic RAS Cooperate to Drive Tumor Progression through CRAF. Cell 2010, 1:209–221.CrossRef 14.